Allen E M, Gengozian N
Transplantation. 1975 Jun;19(6):456-63. doi: 10.1097/00007890-197506000-00002.
Clinical and experimental studies have shown that antithymocyte globulin pretreatment will reduce the severity of the graft-versus-host reaction after allogeneic bone marrow transplantation. To determine whether this was attributable to a persisting cytotoxic factor in the recipients' sera or a result of the "masking" of foreign antigens by the antihymocyte globulin, an experimental schema utilizing a syngeneic transfer of immunocompetent cells was devised. Lethally irradiated mice that had been pretreated with rabbit antimouse thymocyte globulin (RAMTG) were injected with syngeneic spleen or bone marrow cells and their immunological competence was measured by the response to a test antigen, sheep red blood cells. It was found that such pretreatment had an adverse effect on the immunological potential of the infused cells. Thus, the plaque-forming cell response to sheep red blood cell antigen in RAMTG-pretreated recipients injected with spleen cells was reduced when compared to the saline or normal rabbit globulin-treated controls. The immunological recovery of lethally irradiated animals protected with syngeneic bone marrow was also delayed, but not permanently impaired, when the recipients had been pretreated with RAMTG. These effects were evident although the spleen or bone marrow cells had been injected into the RAMTG-pretreated recipients at a time when their sera were devoid of any cytotoxic antibodies. It is speculated that two mechanisms may contribute to this alteration in immune function of the infused cells: (1) that RAMTG exists in the serum in amounts sufficient to attach to receptor sites on lymphocytes or their precursors but insufficient to kill the cells, interfering with the antigen recognition mechanism or migration and homing patterns, or (2) that the RAMTG treatment creates a temporary defect in the microenvironment of the spleen and other hemopoietic tissues, thereby affecting the transplantation and proliferation kinetics of the infused cells.
临床和实验研究表明,抗胸腺细胞球蛋白预处理可减轻异基因骨髓移植后移植物抗宿主反应的严重程度。为了确定这是由于受者血清中持续存在的细胞毒性因子,还是抗胸腺细胞球蛋白“掩盖”外来抗原的结果,设计了一种利用免疫活性细胞同基因转移的实验方案。用兔抗小鼠胸腺细胞球蛋白(RAMTG)预处理的致死性照射小鼠,注射同基因脾细胞或骨髓细胞,并通过对试验抗原绵羊红细胞的反应来测量其免疫能力。发现这种预处理对注入细胞的免疫潜力有不利影响。因此,与用生理盐水或正常兔球蛋白处理的对照组相比,注射脾细胞的RAMTG预处理受者对绵羊红细胞抗原的空斑形成细胞反应降低。当受者用RAMTG预处理时,用同基因骨髓保护的致死性照射动物的免疫恢复也延迟了,但没有永久性受损。尽管在脾细胞或骨髓细胞注入RAMTG预处理受者时,其血清中没有任何细胞毒性抗体,但这些影响仍然很明显。推测有两种机制可能导致注入细胞免疫功能的这种改变:(1)RAMTG在血清中的含量足以附着于淋巴细胞或其前体细胞上的受体位点,但不足以杀死细胞,从而干扰抗原识别机制或迁移和归巢模式;(2)RAMTG处理在脾脏和其他造血组织的微环境中造成暂时缺陷,从而影响注入细胞的移植和增殖动力学。